Prediction of Response of Mutated Alpha-Galactosidase a to a Pharmacological Chaperone

Pharmacogenetics and Genomics - United States
doi 10.1097/fpc.0b013e32830500f4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Prediction of the Responsiveness to Pharmacological Chaperones: Lysosomal Human Alpha-Galactosidase, a Case of Study

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2010English

Alpha-Galactosidase a p.A143T, a Non-Fabry Disease-Causing Variant

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2016English

Co-Administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human Α-Galactosidase a Tissue Uptake and Improves Substrate Reduction in Fabry Mice

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

High Throughput Screening for Inhibitors of Alpha-Galactosidase

Current Chemical Genomics
2010English

Substrate Specificity of .ALPHA.-galactosidase From Mortierella Vinacea.

Agricultural and Biological Chemistry
1990English

Co-Chaperone CHIP Stabilizes Aggregate-Prone Malin, a Ubiquitin Ligase Mutated in Lafora Disease

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2009English

Alpha-2-Macroglobulin, a Hypochlorite-Regulated Chaperone and Immune System Modulator

Oxidative Medicine and Cellular Longevity
BiochemistryMedicineCell BiologyAging
2019English

A Unique Adolescent Response to Reward Prediction Errors

Nature Neuroscience
Neuroscience
2010English

Strong Increase of Leukocyte Apha‐galactosidase a Activity in Two Male Patients With Fabry Disease Following Oral Chaperone Therapy

Molecular genetics & genomic medicine
GeneticsMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy